Last updated: March 4, 2026
What is the Drug Associated with NDC 68382-0591?
NDC 68382-0591 corresponds to Zynlonta (loncastuximab tesirine-lpyl), an antibody-drug conjugate developed by ADC Therapeutics. It is approved by the FDA for relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and other mature B-cell neoplasms.
Market Overview
Indications and Clinical Use
Zynlonta's approved indication is for adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy. It targets CD19-positive B-cell malignancies, fitting into the broader category of immuno-oncology treatments for hematologic cancers.
Competitive Landscape
Key competitors within this space include:
- Yescarta (axicabtagene ciloleucel): CAR-T therapy with indications in similar relapse settings for LBCL.
- Javljari (lisocabtagene maraleucel): Another CAR-T with similar target profiles.
- Polivy (polatuzumab vedotin): An antibody-drug conjugate targeting CD79b.
The market landscape features multiple biologics and gene therapies, with CAR-T therapies commanding significant market share due to their high efficacy and expensive pricing.
Market Penetration and Adoption
- As of late 2022, Zynlonta has obtained FDA approval (April 2021).
- Early adoption has been cautious, due to competition from established CAR-T therapies and pricing considerations.
- Commercial strategies focus on second-line treatment settings where CAR-T may be delayed or contraindicated.
Market Size and Revenue Estimates
Current Market Size
The U.S. market for relapsed/refractory LBCL drugs was approximately $1.3 billion in 2022.[1] Zynlonta's share remains limited, estimated at less than 10% in its initial launch phase due to competition and logistical challenges.
Sales Trends
- Projected sales in 2023 are approximately $50-100 million.
- Growth driven by approvals in additional indications, expansion into earlier lines of therapy, and increasing clinician familiarity.
Geographic Expansion
Plans include approval and commercialization in the EU and Asia-Pacific regions within 12-24 months, potentially doubling the current revenue base. Market entry could occur by 2024–2025, contingent on regulatory reviews.
Price Projections
Current Pricing
- List price per infusion (three doses total): approximately $37,000.
- Treatment cost per patient: $111,000 (assuming three doses).
Competitive Pricing Analysis
| Drug |
Indication |
Price per Course |
Cost per Dose |
Market Share (2022) |
| Zynlonta |
R/R LBCL |
$111,000 |
$37,000 |
<10% |
| Polivy |
R/R LBCL |
$102,000 |
$34,000 |
15% |
| Yescarta |
R/R LBCL (CAR-T) |
$373,000 |
N/A |
60% (overall)* |
*Yescarta's high price reflects its CAR-T nature and one-time administration.
Future Price Trends
- Price reduction pressures are likely to emerge as competition intensifies, particularly if biosimilars or generics are approved or if manufacturing costs decrease.
- Further indication approvals (e.g., earlier treatment lines, combination therapies) could sustain price levels, assuming clinical benefit justifies premium pricing.
Factors Influencing Price and Market Penetration
- Reimbursement policies: CMS and private insurers influence net price and uptake.
- Clinical efficacy: Superior outcomes could sustain premium pricing.
- Manufacturing costs: Cost improvements could lower prices over time.
- Regulatory decisions: Additional indications enhance market size, supporting maintained or increased pricing.
Regulatory and Policy Environment
- The FDA’s accelerated approval pathway facilitated Zynlonta’s swift market entry.
- Payers may require real-world effectiveness data before broader coverage.
- Reimbursement negotiations could influence net pricing, particularly in the outpatient infusion setting.
Key Takeaways
- Zynlonta addresses a significant unmet need in relapsed/refractory LBCL but faces intense competition from CAR-T therapies.
- The current U.S. market for Zynlonta is approximately $50-100 million, with upside as indications expand.
- Pricing is aligned with similar antibody-drug conjugates but may face downward pressure as volume increases and competitors develop parallel therapies.
- International expansion, new indications, and combination regimens are potential catalysts for growth.
- Cost management and demonstrated clinical value will remain central to maintaining pricing power.
FAQs
Q1: Will Zynlonta’s price decrease as biosimilars enter the market?
A1: Likely, as biosimilar competition typically drives prices downward, but no biosimilar approvals for Zynlonta have been announced yet.
Q2: How does Zynlonta’s efficacy compare with CAR-T therapies?
A2: Zynlonta provides a non-cell therapy option with moderate response rates (~48%) and lower toxicity, advantageous for patients ineligible for CAR-T.
Q3: What is the long-term revenue potential for Zynlonta?
A3: Dependent on clinical data, expanding indications, and market penetration; estimates suggest several hundred million dollars annually if growth trends hold.
Q4: Are reimbursement challenges expected for Zynlonta?
A4: Yes. Payer policies will influence drug adoption, especially given high costs and competitive alternatives.
Q5: What regulatory milestones could influence the market?
A5: Approval for earlier lines of therapy, combination approvals, and expanded indications could significantly increase market size and pricing flexibility.
References
- IQVIA. (2022). Pharmaceutical Market Estimates: Oncology Drugs.
- U.S. Food and Drug Administration. (2021). FDA approves Zynlonta for relapsed or refractory large B-cell lymphoma.
- MarketWatch. (2022). Antibody-drug conjugates: The state of the industry.
- Evaluate Pharma. (2022). Global oncology drug sales and forecasts.
- BlueCross BlueShield. (2023). Reimbursement policies for novel hematologic therapies.
